Most GLP-1 analogs have been evaluated in MAFLD/MASH with varying degrees of success, but fell short of approval until semaglutide, a long-acting GLP-1 agonist, was approved for treatment of MASH in 2025 [3]. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.